Sustaining Generic Medicines Markets in Europe

More documents

Recommendations

Info

Sustaining generic medicines markets 387 Austria7.1 Generic medicines marketIn the context of a generic medicines policy that consists of some supply-side measures, but nodemand-side measures, the Austrian generic medicines market has developed slowly over theyears. Market share of generic medicines has grown from 5.5% in 1994 to 8.8% in 2004 in termsof value of consumption and from 9.2% in 1994 to 15.8% in 2004 in terms of volume ofconsumption.Figure 8. Market share of generic medicines by value in Austria, 1994-2004Market share of generic medicines100%80%60%40%20%0%5,5% 5,8% 5,9% 6,1% 5,8% 5,7% 5,8% 6,1% 6,5% 7,6% 8,8%1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004YearFigure 9. Market share of generic medicines by volume in Austria, 1994-2004Market share of generic medicines100%80%60%40%20%0%9,2%9,8%10,2%10,6%10,7%11,0%11,5%12,3%13,1%15,8%14,3%1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004Year
Sustaining generic medicines markets 397.2 Generic medicines policy7.2.1 PricingThe Austrian medicine market is characterised by low prices (Pharmig, 2002). In the 1990s,generic medicines were included in the social insurance fund’s approved list of reimbursedmedicines if they were priced at least 30% lower than the originator medicine. This was followedby a demand to reduce the price of the originator medicine by 23%. This means that genericmedicines tended to be around 7%-10% cheaper than originator medicines.In 2004, a new pharmaceutical pricing policy came into force, with medicine prices based onaverage prices of some EU countries. Furthermore, prices of generic medicines and originatormedicines that are off-patent were regulated as follows. The first generic medicine is priced 44%in 2004, 46% in 2005, and 48% from 2006 onwards below the price level of the originatormedicine. The price of the originator medicine needs to decrease by 30% three months afterentry of the first generic medicine. The price of the second generic medicine is 15% below theprice level of the first generic and the third generic medicine is priced 10% below the level of thesecond generic medicine. Additionally, the prices of the originator, first and second genericmedicines need to go down to the price level of the third generic medicine not later than threemonths following the market entry of the third generic medicine. The fourth and any subsequentgeneric medicine needs to be at least 0.10 € cheaper than the least expensive generic medicine.7.2.2 Reference pricingAustria does not have a RPS.7.2.3 Incentives for physiciansPhysicians who have a contract with a social insurance fund need to observe guidelines on thecost-effective prescribing of medicines. Adherence to guidelines is monitored by social insurancefunds by comparing prescription rates among peers. Failure to comply with guidelines may resultin a reprimand, obligation to refund the social insurance fund or loss of contract with the fund.Physician generic prescribing targets have been successfully implemented in Vienna, but havenot been extended to other provinces. There is no legal obligation or encouragement forphysicians to prescribe by INN. However, the hospital discharge letter points out that physicianscan prescribe a generic medicine. Physicians are assisted in their prescribing by computerisedprescribing and a medicine database.
Page 4: Sustaining generic medicines market
Page 13: Sustaining generic medicines market
Page 16 and 17: Sustaining generic medicines market
Page 90 and 91:
Sustaining generic medicines market
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106:
Generic medicines create major savi
show all

Sustaining Generic Medicines Markets in Europe

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?